UNSPSC 51382100: Nonsteroidal anti inflammatory carbazoles

Nonsteroidal anti inflammatory drugs made from benzo-indoles similar to carbolines which are pyrido-indoles, often from indole.

UNSPSC 51382100 Nonsteroidal anti inflammatory carbazoles is a Class code that sees state and local procurement activity focused on pharmaceutical supply and community health initiatives, though the recent opportunities tagged under this code diverge significantly from its nominal scope. The three recent solicitations show state and local governments buying naloxone and drug deactivation systems, generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing, and exploring direct-to-manufacturer prescription programs. Issuing bodies include county health departments (Seminole County, Florida), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving multiple state and local government facilities across participating jurisdictions including Oregon). The work ranges from tactical procurement of specific drug-deactivation supplies to strategic sourcing of broad generic pharmaceutical catalogs and pilot programs for alternative distribution models outside traditional pharmacy benefit manager channels.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2026, and a two-year initial contract term plus one-year renewal option. The Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on direct-to-manufacturer prescription programs for self-insured employee health plans and state agencies, functioning as exploratory market intelligence before formal RFP issuance. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, released RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a March 26, 2026, response deadline and July 1, 2026, contract effective date; vendors must maintain relationships with three authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act requirements, with evaluation weighted 75 percent on price competitiveness.